Efficacy, Safety, Tolerability And Pharmacokinetics Of Tofacitinib For Treatment Of Systemic Juvenile Idiopathic Arthritis (Sjia) With Active Systemic Features In Children And Adolescent Subjects
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 18 Apr 2018
At a glance
- Drugs Tofacitinib (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 06 Mar 2018 Planned End Date changed from 1 Apr 2023 to 6 Apr 2023.
- 06 Mar 2018 Planned primary completion date changed from 1 Apr 2023 to 6 Apr 2023.
- 06 Mar 2018 Planned initiation date changed from 1 May 2018 to 25 May 2018.